Vaccine Stocks In The Coming Vaccine Glut
Submitted by Thomas Kirchner of Camelot Portfolios Production capacity is built for billions of doses of vaccines. Vaccines are priced for high income countries but unaffordable for poorer countries. Vaccine manufacturers may be less profitable than stock prices imply. Stocks of the developers of Corona-vaccines have been among last year’s top performers. Moderna, for example,…